FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

/PRNewswire/ — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to reduce the risk of kidney disease…

Share This Post
Related Articles
Receive the latest updates

Subscribe To
Our Quarterly Newsletter

Get notified about new blog posts, case studies, white papers, and more!